Leave a comment share Discovering how stomach cancer spreads A cancer cell. Cancer of the stomach is the second most common cause gastric cancer targeted therapy death due to malignant disease worldwide Scientists at the University of Liverpool have found that the production of a protein that prevents the growth and spread of cancerous cells is impaired in patients with gastric cancer.
Cancer of the stomach is the second most common cause of death due to malignant disease worldwide. New gastric cancer targeted therapy findings at Liverpool, however, could contribute to the development of future gastric cancer therapies by restoring the functions of a protein called, TGFÎ²ig-h3.
Development of future therapies The protein is released by cells called myofibroblasts, which form part of the supporting tissue around cancer cells.
Myofibroblasts are highly mobile cells that produce and release multiple substances that change cancer behaviour by altering their environment, leading to the growth and spread of cancerous cells. Scientists at Liverpool have now discovered that in tumours of advanced gastric cancer patients, the myofibroblasts decrease the release of a protein that would normally inhibit the growth and spread of the disease.
This allows targeting of treatments to the area, but in advanced stages of the disease the effects of this protein are diminished, increasing the risk of the disease spreading to other parts of the body. It is published in Carcinogenesis.